R2 Technologies Disrupts the Aesthetics Industry with Its Groundbreaking Glacial Rx™ Treatment The first & only treatment powered by cooling technology proven to gently remove age spots

R2 Technologies Inc. ("R2") the leader in CryoAesthetic™ medical devices, launches Glacial Rx™, the first revolutionary in-office CryoAesthetic™ age spot removal treatment, FDA-cleared to remove benign lesions and temporarily reduce pain, swelling and inflammation.

Developed by the pioneers of CoolSculpting and Fraxel, Glacial Rx is the first and only technology that uses Cryomodulation™ to improve skin appearance and freeze melanin at the source. The treatment harnesses the power of cold, using patented cooling technology, to suppress melanin production and remove unwanted dark spots. It also brightens, soothes, and renews skin for peak results and no downtime.

“I am excited to partner with Glacial Rx to be among the first to offer this novel treatment in my practice,” says Board Certified Dermatologist Dr. Gregory Nikolaidis. “I believe it will be a game-changer in the category of cryoaesthetics, offering the opportunity to treat new patients who are looking for a comfortable solution to remove benign lesions.”

The Glacial Rx System is an FDA Class II Device administered by trained healthcare professionals. Effective on most skin types, Glacial Rx delivers the best possible outcomes to remove age spots without the contraindications, risks, side effects or limitations associated with heat modalities.





Glacial Rx System

Before Treatment

After 1 Treatment, 1 Month Follow-Up





In partnership with one of the world’s fastest growing cosmeceutical skincare brands, Allies of Skin, Glacial Rx offers a curated topical regimen made with optimal active ingredient concentrations that can be provided alongside the treatment at the healthcare professional's discretion. The treatment consists of:

• Cool: The cold plate is applied to a spot for 15-20 seconds; no topical anesthetics or numbing agents needed.
• Calm: The cooling handpiece is gently moved across the face to reduce redness and puffiness, clearing the way for skin to better absorb potent topicals.
• Protect: Serums containing protective antioxidants and brightening agents can be applied, shielding the skin from environmental aggressors. Post-treatment take-home topical offerings, formulated with skin-beneficial plant derived actives, aid in skin recovery, accelerate skin’s desquamation process and re-epithelialization, and dramatically boost antioxidant activity to fight free radical damage.

“It took us a long time to ensure that we were creating a best-in-class treatment, giving unparalleled results and superior experiences to our patients, and we are thrilled to finally bring this matchless innovation to market,” says Tim Holt, R2 Chief Executive Officer. According to a recent clinical study, 93% of spots improved at 2 months[1]; and another showed that 90% of patients said their skin was rejuvenated, brighter or more even at 1 month[2].

Launching this month in dermatology offices and med spas nationwide, Glacial Rx was named among ‘2021 Launches Doctors are Buzzing About’ by RealSelf, the leading and most trusted source to educate on cosmetic procedures. R2 is continuing to facilitate Glacial Rx system orders for practices to offer the treatment. Learn more about R2 Technologies and Glacial Rx at glacialskin.com and follow the company on LinkedIn.



About R2 Technologies: Headquartered in Silicon Valley, R2 Technologies is a world leader in CryoAesthetic™ medical devices. In 2014, Pansend Life Sciences, LLC and Blossom Innovations, LLC founded R2 Technologies and licensed exclusive intellectual property from Massachusetts General Hospital. In 2019, R2 brought on another strategic partner, Huadong Medicine Co., Ltd. In close collaboration with these partners and the brand’s scientific founders and world-famous luminaries in aesthetic medicine, Drs. Rox Anderson, Dieter Manstein, and Henry Chan, R2 focuses on the development, engineering, clinical research, and commercialization of groundbreaking technologies for aesthetic providers and consumers. Since inception, R2 has raised $62 million in financing led by a world-class team of experts within the aesthetics industry and was named winner of the 2nd Annual Aesthetics Tech Summit LaunchPad SBDC, hosted by Octane, a company committed to making resources, capital and mentorship available to tech and medtech startups.

_________________________________________________________________________________________________

[1] Evaluation of the Dermal Cooling System for the Enhanced Treatment of Benign Pigmented Lesions and Common Skin Conditions - Interim Analysis - Nov 2020 - TD-0993

[2] Evaluation of a New Dermal Cryotherapy System for the Treatment of Benign Pigmented Lesions - Interim report - May 2018 - TD-0992